Sorry, you need to enable JavaScript to visit this website.

All announcements

Announcement Date

Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA

On 5/15/2018, Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen® and Procrit® (epoetin alfa), for all indications of the reference product. Please see the full press release via the link below for further details.
May 15, 2018

Ibrance (palbociclib) Recommended Dose Modifications for Adverse Reactions

A new dose modification interactive tool for Ibrance is now available on Ibrance Medication Page.
May 3, 2018

Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years.

April 23, 2018

Chat Online service is currently unavailable

Chat Online service is currently unavailable. If you have a medical question regarding a Pfizer prescription product, please click here to return to the website to search our document database or submit your question via the web form here. Alternatively, you may contact us by telephone at 1-800-438-1985, 8am-7pm ET Monday-Friday.
April 13, 2018

Limited Release of Quillivant XR

March 23, 2018

Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers

March 23, 2018

Transparency on Every Level - Supply Shortage Recovery Plan and Plans to Mitigate Shortages in the Future

Pfizer deeply understands the impact of shortages of some products in our portfolio on customers and their patients, and is doing everything possible to resolve current shortages. We have developed an in-depth video series to provide our customers with open and transparent communication throughout our recovery efforts. Watch below to hear from individuals at every level of the organization as they discuss progress against our supply shortage recovery plan and plans to mitigate shortages in the future.
March 19, 2018

Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis

March 13, 2018

US Food and Drug Administration Extends Action Date for Xeljanz (Tofacitinib) Supplemental New Drug Application in Ulcerative Colitis by Three Months

December 13, 2017

Pfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab ozogamicin)

Pfizer Inc. announced that the U.S. Food and Drug Administration approved MYLOTARG™ (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML. MYLOTARG is the first therapy with an indication that includes pediatric AML. It is also the only AML therapy that targets CD33, an antigen expressed on AML cells in up to 90% of patients.
September 12, 2017

Overview of Quillivant XR (video presentation)

February 22, 2017

Overview of QuilliChew ER (video presentation)

February 22, 2017